Overview
BNTX market data
Price History
BNTX price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$4.70 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.25 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -63.6% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $79.52 – $124.00 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $23.1B · P/B 1.03 · P/S 7.56.
Company News
BioNTech Just Named a New CEO. Here's What Guido Oelkers' Appointment Means for the Stock.The Motley Fool · Aug 13, 2026, 3:01 PM
Trump Says Administration Recognizing Childhood Vaccine Recommendations For Only 11 Core Vaccinations; Hepatitis B, COVID-19, Influenza No Longer Recommended For All ChildrenBenzinga · Aug 10, 2026, 7:00 PM
Citigroup Maintains Buy on BioNTech, Lowers Price Target to $125Benzinga · Aug 5, 2026, 6:59 PM
Evercore ISI Group Maintains Outperform on BioNTech, Lowers Price Target to $130Benzinga · Aug 5, 2026, 2:08 PM
BNTX stock has given up its prior loss. BioNTech shares were trading lower after the company reported worse-than-expected Q2 financial results and cut its FY26 sales guidance below estimates.Benzinga · Aug 4, 2026, 3:01 PM
BioNTech shares are trading lower after the company reported worse-than-expected Q2 financial results and cut its FY26 sales guidance below estimates.Benzinga · Aug 4, 2026, 1:31 PM
BioNTech Lowers FY2026 Sales Guidance from $2.328B-$2.678B to $1.860B-$2.209B vs $2.500B EstBenzinga · Aug 4, 2026, 10:46 AM
BioNTech Q2 Adj. EPS $(2.58) Misses $(2.34) Estimate, Sales $122.766M Miss $182.020M EstimateBenzinga · Aug 4, 2026, 10:45 AM
BioNTech Names Orphan Biovitrum's Guido Oelkers As New CEO, Replacing Ugur SahinBenzinga · Aug 3, 2026, 9:14 AM
European Commission Grants Marketing Authorization For Pfizer And BioNTech's 2026-27 COVID-19 Vaccine FormulaBenzinga · Jul 29, 2026, 8:35 PM